A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 54, Issue 5, 2014, Pages 412-417

  Ayres, Alice C ^a,b,d   Whitty, Jennifer A ^b,c   Ellwood, David A ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Benefits; Consequences; Cost; Implementation; Noninvasive prenatal testing

Indexed keywords

ADULT; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOWN SYNDROME; FEMALE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NON INVASIVE PROCEDURE; PRENATAL DIAGNOSIS; COMPARATIVE STUDY; ECONOMICS; FETAL DISEASES; FIRST TRIMESTER PREGNANCY; PREGNANCY;

ADULT; COST-BENEFIT ANALYSIS; DOWN SYNDROME; FEMALE; FETAL DISEASES; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL DIAGNOSIS;

EID: 84907807431     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/ajo.12223     Document Type: Article

References (31)

1. Chiu RW, Akolekar R, Zheng YW et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011; 342: c7401.
2. Ehrich M, Deciu C, Zwiefelhofer T et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011; 204: 205.e1-11.
3. Palomaki GE, Kloza EM, Lambert-Messerlian GM et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011; 13: 913-920.
4. Sehnert AJ, Rhees B, Comstock D et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem 2011; 57: 1042-1049.
5. Ashoor G, Syngelaki A, Wagner M et al. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206: 322.e1-5.
6. Bianchi DW, Platt LD, Goldberg JD et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012; 119: 890-901.
7. Norton ME, Brar H, Weiss J et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 207: 137.e1-8.
8. Sparks AB, Struble CA, Wang ET et al. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206: 319.e1-9.
9. Lau TK, Chan MK, Lo PS et al. Clinical utility of noninvasive fetal trisomy (NIFTY) test-early experience. J Matern Fetal Neonatal Med 2012; 25: 1856-1859.
10. Zimmermann B, Hill M, Gemelos G et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn 2012; 32: 1233-1241.
11. Hui L, Hyett J. Noninvasive prenatal testing for trisomy 21: challenges for implementation in Australia. Aust N Z J Obstet Gynaecol 2013; 53: 416-424.
12. Nicolaides KH, Syngelaki A, Ashoor G et al. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012; 207: 374.e1-6.
13. Dan S, Wang W, Ren J et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn 2012; 32: 1225-1232.
14. Verifi Prenatal Test. Sonic Genetics Via SNL Pathology, 2013. [Accessed 18 April 2014.] Available from URL: http://www.sonichealthcare.com/media/80192/9437-mp-verify-6pp-sg-dl-low.pdf
15. Cell Free DNA Testing. Women's Ultrasound Melbourne, 2013. [Accessed 18 April 2014.] Available from URL: http://www.womensultrasound.com.au/cell-free-dna-testing.html.
16. DNA-based Noninvasive Prenatal Testing for Fetal Aneuploidy, College Communique. Royal Australian and New Zealand College for Obstetricians and Gynaecologists, 2014. [Accessed 15 May 2014.] Available from URL: http://www.ranzcog.edu.au/womens-health/college-communiques/1357-dna-based-noninvasive-prenatal-testing-for-fetal-aneuploidy.html.
17. Benn P, Borell A, Chiu R et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2013; 33: 622-629.
18. American College of Obstetricians and Gynecologists. Noninvasive prenatal testing for fetal aneuploidy. Committee opinion No. 545. Obstet Gynecol 2012; 120: 1532-1534.
19. O'Leary P, Maxwell S, Murch A, Hendrie D. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies. Aust N Z J Obstet Gynaecol 2013; 53: 425-433.
20. Susman M, Amor D, Muggli E et al. Using population-based data to predict the impact of introducing noninvasive prenatal diagnosis for Down syndrome. Genet Med 2010; 12: 298-303.
21. Prenatal Screening Tests for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome) and Neural Tube Defects, 2007 College Statement: C-Obs 4. Royal Australian and New Zealand College of Obstetricians and Gynaecologists, 2007. [Accessed 30 August 2013.] Available from URL: https://www.ranzcog.edu.au/doc/prenatal-screening-tests-for-trisomy-21-trisomy-18-and-neural-tube-defects.html.
22. Li Z, Zeki R, Hilder E, Sullivan A. Australia's Mothers and Babies 2010. Cat. no. PER 57. Canberra: AIHW National Perinatal Epidemiology and Statistics Unit, 2012.
23. Loane M, Morris JK, Addor MC et al. Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur J Hum Genet 2013; 21: 27-33.
24. Maxwell S, Brameld K, Bower C et al. Socio-demographic disparities in the uptake of prenatal screening and diagnosis in Western Australia. Aust N Z J Obstet Gynaecol 2011; 51: 9-16.
25. Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 2007; 110: 687-694.
26. Medicare Benefits Schedule Book. Canberra, ACT: Department of Health and Ageing, 2013.
27. Service database. QML pathology [Accessed 20 April 2014], 2014.
28. Service database. Queensland ultrasound for women [Accessed 20 April 2014], 2014.
29. Service database. Sullivan and Nicolaides Pathology [Accessed 20 April 2014], 2014.
30. Ashoor G, Syngelaki A, Poon L et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol 2013; 41: 26-32.
31. Song K, Musci T, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfdna analysis in high risk women based on a U.S. population. J Matern Fetal Neonatal Med 2013; 26: 1180-1185.